Preclinical characterization of Myo-2, a muscle-penetrating mitochondriotropic agent for the treatment of DMD

March 25, 2024

To address the need for novel therapeutic candidates against Duchenne muscular dystrophy (DMD), investigators at Mitorx Therapeutics Ltd. developed a library of novel small-molecule mitochondriotropic agents.

BioWorld Science Conferences New compound Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

New Trump order zeroes in on drug prices

BioWorld

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...

Many US tariffs paused, pharma warned, EU put on notice

BioWorld

The on-again, off-again U.S. tariffs are off again, at least for now, for more than 75 countries that have reached out to the Trump administration to negotiate...